Grail (NASDAQ:GRAL) Reaches New 52-Week High – What’s Next?

Shares of Grail, Inc. (NASDAQ:GRAL) hit a new 52-week high during trading on Monday . The company traded as high as $23.71 and last traded at $23.21, with a volume of 300071 shares trading hands. The stock had previously closed at $22.16.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Guggenheim initiated coverage on shares of Grail in a research note on Thursday, October 17th. They set a “neutral” rating on the stock. Morgan Stanley started coverage on Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective on the stock. Finally, Wolfe Research assumed coverage on Grail in a research note on Friday, November 15th. They issued a “peer perform” rating for the company.

Grail Stock Performance

The company has a 50-day simple moving average of $15.86.

Insiders Place Their Bets

In other Grail news, CEO Robert P. Ragusa sold 123,454 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the completion of the transaction, the chief executive officer now owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This represents a 16.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Aaron Freidin sold 30,452 shares of Grail stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the sale, the chief financial officer now owns 268,277 shares in the company, valued at $3,761,243.54. This trade represents a 10.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders bought 58,829 shares of company stock worth $757,298.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.